Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 13,993 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: combined treatment Clear all

Conditions: Osteoarthritis
Interventions: Sustained Acoustic Device with 2.5% Diclofenac Patch, 2.5% Diclofenac Patches; Device · Drug
Lead sponsor: ZetrOZ, Inc.; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Psoriasis
Interventions: Apremilast and Clobetasol; Combination Product
Lead sponsor: Washington Dermatology Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions: everolimus, lenalidomide, laboratory biomarker analysis, polymorphism analysis, immunohistochemistry staining method, microarray analysis, fluorescence in situ hybridization; Drug · Other · Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Panzem® NCD, Sunitinib Malate; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Madison, Wisconsin

Conditions: Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions: Carfilzomib, Irinotecan; Drug
Lead sponsor: Cancer Research and Biostatistics Clinical Trials Consortium; Network
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more

Conditions: Breast Cancer
Interventions: Ribociclib, Letrozole, Goserelin, Leuprolide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 71
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more

Conditions: Opiate Addiction, Refractory Pain
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypertension
Interventions: losartan potassium / hydrochlorothiazide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Recurrent Non Small Cell Lung Cancer
Interventions: apricoxib/erlotinib, erlotinib/placebo; Drug
Lead sponsor: Tragara Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 47
States / cities: Tucson, Arizona • Bakersfield, California • Los Angeles, California + 44 more

Conditions: Hypertension
Interventions: amlodipine and olmesartan, losartan and HCTZ; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Amnestic Mild Cognitive Impairment
Interventions: Combined Aerobic and Resistance Exercise, Stretching Exercises, Cognitive Training; Behavioral
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 50 Years to 90 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography; Drug · Procedure · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Psoriasis Vulgaris
Interventions: 0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate; Drug
Lead sponsor: Dermatology Consulting Services, PLLC; Network
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma
Interventions: Atezolizumab, Biopsy, Biospecimen Collection, Cobimetinib, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 41
States / cities: Duarte, California • Sacramento, California • South Pasadena, California + 31 more

Conditions: Metabolic Syndrome
Interventions: CAR-191, Placebo; Dietary Supplement · Other
Lead sponsor: Carmel Biosciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Non-Small Cell Lung Cancer
Interventions: Docetaxel, Jin Fu Kang; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Osteoarthritis
Interventions: Hybrid Training using Electrodes and Joint Motion Sensors, Isokinetic Training with Isokinetic Dynamometer; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years to 85 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Prostate Cancer
Interventions: DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes
Interventions: ePID closed loop system, liraglutide; Device · Drug
Lead sponsor: Jennifer Sherr; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Biliary Cancer
Interventions: SPI-1620, Docetaxel; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 3 more

Conditions: Breast Cancer
Interventions: Enzalutamide, Placebo, Paclitaxel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 6
States / cities: Topeka, Kansas • Metairie, Louisiana • The Bronx, New York + 3 more

Conditions: Crohn Disease, Ulcerative Colitis (UC)
Interventions: Psychologist-administered Cognitive Behavioral Therapy, Self-Administered Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lymphoma, Solid Tumor (Excluding CNS)
Interventions: Pixantrone; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 6 Months to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Soft Tissue Sarcoma, Sarcoma,Soft Tissue
Interventions: Talimogene Laherparepvec, Neoadjuvant Radiation, Surgery; Drug · Radiation · Procedure
Lead sponsor: John Rieth; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Sustained Acoustic Medicine for Osteoarthritis Pain

Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions

APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

The BANGALORE Study; Combination of Berberine, Lipoic Acid, and Picrorhiza

Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer

Combined Application of Electrical Stimulation and Volitional Contractions for Muscle Strengthening and Knee Pain Inhibition (Seated Study)

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec